(IGR: 3-1) | International Glaucoma Review #

Top 8 from the XTH annual conference of the Glaucoma Society of India

Application of newer diagnostic testing and therapeutic decisions should be strongly evidence based
The best "neuroprotector" available still, is the lowering of IOP
In India population based screening for glaucoma is neither economically nor logistically possible
Detection of "in our face glaucoma" by opportunistic screening (clinic) is currently the method of choice
FDP, in the screening mode, has a high sensitivity and specificity for detection of glaucomatous field defects
In India chronic angle closure glaucoma is at least as common as primary open angle glaucoma which should be a diagnosis of exclusion
There was good clinical agreement between SITA and Full Threshold in glaucoma diagnosis
As expected, Xalatan and Alphagan have been found to be effective in Indian eyes